Evan Seigerman
Stock Analyst at BMO Capital
(3.92)
# 566
Out of 4,784 analysts
140
Total ratings
53.26%
Success rate
8.69%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Market Perform | $156 → $139 | $138.37 | +0.46% | 26 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $110 → $115 | $111.79 | +2.87% | 15 | Feb 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $566 → $520 | $492.69 | +5.54% | 14 | Dec 20, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $60.02 | +1.63% | 11 | Nov 12, 2024 | |
| INCY Incyte | Reiterates: Underperform | $48 → $52 | $60.60 | -14.19% | 12 | Oct 30, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $128 → $114 | $113.16 | +0.74% | 14 | Oct 17, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $1,001 → $1,101 | $822.51 | +33.86% | 8 | Aug 9, 2024 | |
| IRON Disc Medicine | Reiterates: Outperform | $50 → $70 | $52.36 | +33.69% | 5 | Jun 17, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $19.77 | +102.33% | 1 | Feb 28, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $40 | $10.39 | +284.99% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $637.36 | +23.63% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $1.82 | +37.36% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $306.95 | -20.83% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $5.95 | +101.85% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $25.21 | +138.00% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $27 | $1.32 | +1,945.45% | 2 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $1.26 | +2,280.95% | 3 | May 12, 2020 |
Biogen
Feb 13, 2025
Maintains: Market Perform
Price Target: $156 → $139
Current: $138.37
Upside: +0.46%
Gilead Sciences
Feb 12, 2025
Maintains: Outperform
Price Target: $110 → $115
Current: $111.79
Upside: +2.87%
Vertex Pharmaceuticals
Dec 20, 2024
Maintains: Outperform
Price Target: $566 → $520
Current: $492.69
Upside: +5.54%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $60.02
Upside: +1.63%
Incyte
Oct 30, 2024
Reiterates: Underperform
Price Target: $48 → $52
Current: $60.60
Upside: -14.19%
Neurocrine Biosciences
Oct 17, 2024
Maintains: Market Perform
Price Target: $128 → $114
Current: $113.16
Upside: +0.74%
Eli Lilly and Company
Aug 9, 2024
Maintains: Outperform
Price Target: $1,001 → $1,101
Current: $822.51
Upside: +33.86%
Disc Medicine
Jun 17, 2024
Reiterates: Outperform
Price Target: $50 → $70
Current: $52.36
Upside: +33.69%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $19.77
Upside: +102.33%
Replimune Group
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $10.39
Upside: +284.99%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $637.36
Upside: +23.63%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $1.82
Upside: +37.36%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $306.95
Upside: -20.83%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $5.95
Upside: +101.85%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $25.21
Upside: +138.00%
Aug 13, 2021
Maintains: Outperform
Price Target: $30 → $27
Current: $1.32
Upside: +1,945.45%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $1.26
Upside: +2,280.95%